What Lumentum Adds To A Portfolio Is Not Safety — And At These Levels, That's The Problem

The Lumentum story has two halves. The first half — the one that pushed the stock up 661% over the past rolling year, from a 52-week low of $111 to a peak near $1,086 — is about extraordinary fundamentals riding an AI optical infrastructure boom. The second half, the one most articles about this stock seem to miss, is about what happens when those fundamentals are already reflected in a price that leaves zero room for execution slip.

A recent piece argued that what Lumentum adds to a portfolio is not safety. That's true. But it's also beside the real question: after a rally of this magnitude, does the risk/reward still support conviction?

The numbers that built the rally are hard to dismiss. In its third quarter of fiscal 2026, Lumentum reported $808.4 million in revenue, up 90% year over year. Non-GAAP earnings per share came in at $2.37, beating the consensus estimate of $2.27. Gross margin expanded to 47.9%, up from 33% in fiscal 2024. Non-GAAP operating margin hit 32.2%, with management guiding to 35–36% in the fourth quarter. Revenue has essentially doubled in five quarters, from $425 million in fiscal 2025 Q3 to $808 million in Q3 of fiscal 2026, with the fourth quarter on track to break $1 billion for the first time.

That kind of operating leverage at that growth rate is what makes the stock compelling. It's also what makes the valuation question unavoidable.

The Moat That Justified The First Half

Before worrying about the price, the question is whether the competitive position survives scrutiny. Here's where Lumentum earns its reputation.

The company is undershipping demand for electro-absorption modulated lasers — the components that enable the high-speed optical interconnects AI data centers require — by more than 30%. The supply gap is even wider for pump lasers. Indium phosphide substrate supply has tightened as order volumes exceed long-term agreements. This isn't a company chasing demand it can't fulfill; it's a company that has become demand-constrained on its own supply chain.

Management's response is the Greensboro, North Carolina facility, being retrofitted for indium phosphide laser production. The CEO described it as capable of supporting up to $5 billion in incremental revenue. That's the sort of optionality that would matter for any semiconductor story. It won't contribute meaningfully until around 2028, which means the near-term growth engine is running on existing capacity and supply discipline.

Then there's the next layer: co-packaged optics and near-packaged optics. CPO (which integrates optical engines directly with silicon chips) is expected to generate between $50 million and $100 million in incremental revenue this quarter — significant, given it was effectively zero revenue a few quarters ago. But the CEO described near-packaged optics as potentially an even larger opportunity, because it places the optical engine outside the chip substrate and requires more optical lanes per rack, favoring Lumentum's laser supply model. When those deployments cross $200 million per quarter in revenue, the scale-up thesis moves from forecast to confirmed execution.

The moat isn't cracking under this pressure. If anything, supply constraints are reinforcing it.

The Valuation Problem The First Half Doesn't Solve

Here's where the story changes. Consensus estimates project EPS to nearly quadruple over the next 15 months: roughly $2.96 in fiscal Q4 2026, $3.61 in Q1 2027, $4.35 in Q2 2027, and $5.52 in Q3 2027. That sums to approximately $16.44 in forward earnings. At the current price of around $888, the stock trades at roughly 54 times next-year earnings.

Compare that to the trading history. A year ago, at a price near $111, the same growth trajectory would have looked like a generational opportunity. Today, the trajectory is real, but the price has moved 8x. The disconnect is no longer between valuation and growth — it's between valuation and flawless execution. At 54x forward earnings, the market is assuming every quarterly beat, every margin expansion, every capacity ramp, every CPO and NPO adoption curve stays on track.

The forward EV/EBITDA of roughly 33x is comparable to Arista Networks and below Ciena, which suggests the stock isn't absurdly expensive relative to its optical infrastructure peers. But that peer comparison only works if you accept that Lumentum's growth rate — nearly doubling revenue annually — is going to persist through a period where hyperscaler spending patterns are already showing signs of normalization pressure.

The Pullback That Shouldn't Be Dismissed

The June-July pullback, when the stock fell roughly 20% from its peak amid a broader semiconductor and AI-linked selloff, is worth paying attention to. The rebound to the $880s looks like recovery. But the pattern matters: a stock that can shed $200 from its peak in a single month after posting a 900% return in a year is not exhibiting stability. It's exhibiting what happens when expectations built at $1,086 meet the reality that not every earnings cycle delivers perfect beats with upgraded guidance.

Even after the Q3 beat, the stock declined 5% on the reporting date. That kind of reaction — beat and drop — is a signal that the marginal buyer at these levels is already holding a position and selling into good news rather than adding.

August 11 Is The Next Gate

Lumentum reports fiscal Q4 earnings on August 11, after market close. Analysts are projecting roughly $2.86 in non-GAAP EPS against consensus revenue near $1.1 billion. Management has already guided to $960 million to $1.01 billion in revenue and $2.85 to $3.05 in non-GAAP EPS. The range is narrow, which means the market's reaction will hinge less on whether the company hits the midpoint and more on what management says about CPO and NPO adoption curves, Greensboro ramp timing, and the supply-demand imbalance heading into fiscal 2027.

If management walks that range, confirms the CPO/NPO momentum is accelerating, and raises the outlook, the stock could push back toward $1,000. But at that price, you're paying 60x forward earnings for a company whose biggest growth drivers — co-packaged optics and the Greensboro expansion — are still largely future tense.

If the company delivers in-line results but signals any caution on supply capacity, hyperscaler demand pacing, or margin trajectory, the pullback from here could be swift. Goldman Sachs has already begun flagging valuation and "earnings bubble" concerns across the high-end AI infrastructure complex. Lumentum, trading at a valuation that assumes perfection, sits squarely in that zone.

What To Do

I don't think investors need to chase Lumentum at these levels. The setup is not broken — the fundamentals are real, the moat is intact, the growth trajectory is accelerating. But the risk/reward at $888 is materially different from what it was at $500, or $300, or $111.

The more constructive posture is to wait. A deeper pullback — whether triggered by a conservative Q4 print, a broader AI infrastructure correction, or the kind of sector rotation that routinely resets extended tech valuations — would create the kind of entry where the growth rate actually supports the price again. The 50-day moving average sits around $818; the 200-day is near $618. A move toward either would reestablish the disconnect between forward valuation and growth that makes this stock compelling in the first place.

For existing holders, the August 11 report is your checkpoint. If the company delivers and raises, staying invested makes sense — but trimming into strength near the prior highs isn't a bad risk-management move either. If the report falls short or guidance softens, the downside from here is real.

The lesson isn't that Lumentum is a bad company. It's that great companies at stretched prices are a different setup than great companies at stretched prices with room to grow. The growth is still there. The room is not.

AInvest's aggregate signal labels the stock a Buy, and the consensus leans that way too. But consensus ratings don't adjust for the fact that the stock has already done the work the thesis promised — it's just priced that work in.